Home TMU Sitemap FAQ Links
正體中文
Home Ongoing Clinical Trials
Ongoing Clinical Trials

Institution
Principal Investigator
Protocol Title
Keyword
TMU-JIRB No. Protocol Title Institution / Principal Investigator Type of Study Phases of Clinical Trials for Drugs
N202603154 Feasibility, toxicity, and biological effect of bortzomib with chemotherapy in patients with malignant rhabdoid tumors New Drug Phase Ⅲ
N202603155 A Phase 3 Randomized, Double-Blind, Placebo-Controlled Study to Investigate the Efficacy and Safety of Once Weekly Eloralintide in Adult Participants with Persistent Obesity or Overweight Treated with a Weekly Incretin, with and without Type 2 Diabetes (ENLIGHTEN-6) New Drug Phase Ⅲ
N202603156 A Phase 2, Open-label, Multicohort Study of Rinatabart Sesutecan (Rina-S) in Participants with Non-Small Cell Lung Cancer New Drug Phase Ⅰ
N202604021 A pilot clinical investigation of MB828 Nasal Spray for the treatment of moderate-to-severe allergic rhinitis: A safety and preliminary efficacy assessment. New Drug Phase Ⅰ
N202604033 A Phase 2 Study Evaluating the Safety and Efficacy of Neoadjuvant Amivantamab in Combination with Lazertinib or Chemotherapy in Resectable EGFR-Mutated Non-Small Cell Lung Cancer New Drug Phase Ⅱ
N202604046 Randomized, Two-Cohort, Open Label, Phase 3 Clinical Trial of N-803 Plus Tislelizumab or Prior Failed Immune Checkpoint Inhibitor and Docetaxel Versus Docetaxel Monotherapy in Participants with Advanced or Metastatic Non-Small Cell Lung Cancer Who Have Acquired Resistance to Immune Checkpoint Inhibitor Therapy New Drug Phase Ⅲ
N202604057 AN INTERVENTIONAL, OPEN-LABEL, PHASE 2 STUDY TO INVESTIGATE THE SAFETY AND EFFICACY OF PF-08634404 MONOTHERAPY OR IN COMBINATION IN ADULT PARTICIPANTS WITH EARLY-STAGE RESECTABLE OR LOCALLY ADVANCED UNRESECTABLE NON-SMALL CELL LUNG CANCER New Drug Phase Ⅱ
N202604087 A Multicenter, Open-label, Dose-escalation, Phase Ia/Ib Study to Evaluate the Safety, Pharmacokinetics, Pharmacodynamics and Preliminary Efficacy of CKD-512 Monotherapy and in Combination with Pembrolizumab in Subjects with Advanced or Metastatic Solid Tumor Bioavailability / Bioequivalence (BA/BE) NA
N202604088 A Phase 3, Double-blind, Placebo-controlled, Randomized Study to Assess the Efficacy and Safety of ASP3082 in Combination with mFOLFIRINOX or NALIRIFOX as First-line Treatment in Participants with KRAS G12D-mutated Metastatic Pancreatic Adenocarcinoma New Drug Phase Ⅱ
N202604089 A Multicenter, Double-blind, Randomized, Placebo-controlled Study to Evaluate Efficacy and Safety of Seltorexant as Monotherapy in Adult and Elderly Participants With Major Depressive Disorder (MDD) and an Open-label Long-term Extension Treatment with Seltorexant New Drug Phase Ⅲ
1 2 20 21 22 23 24 25 26 31 32 / 32

TOP